our mission

Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target¹⁻³ with novel, oral small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.

Pharvaris is committed to a strong collaboration, closely partnering with patient organizations as well as experts in the HAE community. Throughout the company, we aim to build trust and ongoing dialogue with all members of the community working with and for those with HAE to support people and their families to build knowledge, awareness, education and further HAE research.

¹ Cicardi M et al N Engl J Med 2010 363 532 541
² Lumry WR et al Ann Allergy Asthma Immunol 2011 107 529 537
³ Maurer M et al Clin Exp Allergy 2022 52 1048 1058

consider all those
impacted by our
Mission and what we do

considering
others
care-fully

Prioritize rigorous,
well-informed
decision making based
on robust critical thinking,
pragmatism and
productive challenge

ensuring rigor
&
diversity
of thought

Trust and respect
expertise, experience
and decisions made

leading
with
trust

Have the freedom to
contribute, knowing we
will be listened to, and
recognize everyone has a
responsibility to speak up

contributing
freely

management team

Berndt Modig

Berndt Modig

Chief Executive Officer, Director

Morgan Conn, Ph.D.

Morgan Conn, Ph.D.

Chief Business Officer

Annick Deschoolmeester

Annick Deschoolmeester

Chief Human Resources Officer

Jochen Knolle, Ph.D.

Jochen Knolle, Ph.D.

Chief Scientific Officer, Chief Operating Officer

Anne Lesage, Ph.D.

Anne Lesage, Ph.D.

Chief Early Development Officer

Peng Lu, M.D., Ph.D.

Peng Lu, M.D., Ph.D.

Chief Medical Officer

Joan Schmidt, J.D.

Joan Schmidt, J.D.

Chief Legal Officer

Wim Souverijns, Ph.D.

Wim Souverijns, Ph.D.

Chief Community Engagement & Commercial Officer

Anna Nijdam

Anna Nijdam

Head of Finance, Principal Accounting Officer

board of directors

David Meeker, M.D.

David Meeker, M.D.

Chair of the Board

Elisabeth Björk, M.D.

Elisabeth Björk, M.D.

Director

Anne Marie de Jonge Schuermans

Anne Marie de Jonge Schuermans

Director

Robert Glassman, M.D.

Robert Glassman, M.D.

Director

Berndt Modig

Berndt Modig

Chief Executive Officer, Director

Viviane Monges

Viviane Monges

Director, Audit Chair

Hans Schikan, Pharm.D.

Hans Schikan, Pharm.D.

Vice Chair of the Board

scientific advisors

Aleena Banerji, M.D.

Aleena Banerji, M.D.

Konrad Bork, M.D.

Konrad Bork, M.D.

Marcus Maurer, M.D.

Marcus Maurer, M.D.

Marc Riedl, M.D.

Marc Riedl, M.D.